Benefit-Risk Profile of DAPT Continuation Beyond 1 Year after PCI in Patients with High Thrombotic Risk Features as Endorsed by 2018 ESC/EACTS Myocardial Revascularization Guideline
ConclusionsAmong patients with ESC-endorsed HTR who were free from major ischemic or bleeding events 1 year after coronary stenting, continued DAPT beyond 1 year might offer better effectiveness in terms of atherothrombotic events and comparable safety in terms of clinically relevant bleeding compared with ≤ 1-year DAPT. ESC-HTR criteria is an important parameter to take into account in tailor ing DAPT prolongation.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
More News: Academia | Aspirin | Bleeding | Cardiology | Cardiovascular | Clopidogrel | Heart | Heart Attack | Ischemic Stroke | Plavix | Stroke | Thrombosis